278 related articles for article (PubMed ID: 3041925)
1. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.
Rosenberg SA
Ann Surg; 1988 Aug; 208(2):121-35. PubMed ID: 3041925
[TBL] [Abstract][Full Text] [Related]
2. Adoptive therapies: quo vadis?
Clark JW; Longo DL
Pathol Immunopathol Res; 1988; 7(6):442-58. PubMed ID: 3070530
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
4. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
[No Abstract] [Full Text] [Related]
5. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer cell and interleukin-2 inhibitors: their role in adoptive immunotherapy.
Eggermont AM; Sugarbaker PH
Cell Immunol; 1987 Jul; 107(2):384-94. PubMed ID: 3496163
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of H-2-incompatible lymphokine-activated killer (LAK) cells: an approach for successful cancer immunotherapy free from graft-versus-host disease (GVHD) using murine models.
Toshitani A; Taniguchi K; Himeno K; Kawano Y; Nomoto K
Cell Immunol; 1988 Sep; 115(2):373-82. PubMed ID: 3409329
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic uses of interleukin-2 and lymphokine-activated killer (LAK) cells.
Richards JM
Blood Rev; 1989 Jun; 3(2):110-9. PubMed ID: 2673443
[TBL] [Abstract][Full Text] [Related]
9. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
Kimoto Y; Taguchi T
Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
[TBL] [Abstract][Full Text] [Related]
12. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.
Rosenberg SA; Lotze MT; Yang JC; Aebersold PM; Linehan WM; Seipp CA; White DE
Ann Surg; 1989 Oct; 210(4):474-84; discussion 484-5. PubMed ID: 2679456
[TBL] [Abstract][Full Text] [Related]
13. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
[TBL] [Abstract][Full Text] [Related]
14. NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
Rosenberg SA; Lotze MT; Mulé JJ
Ann Intern Med; 1988 Jun; 108(6):853-64. PubMed ID: 3285747
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
Rosenberg SA; Lotze MT
Annu Rev Immunol; 1986; 4():681-709. PubMed ID: 3518753
[No Abstract] [Full Text] [Related]
16. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
Topalian SL; Solomon D; Avis FP; Chang AE; Freerksen DL; Linehan WM; Lotze MT; Robertson CN; Seipp CA; Simon P
J Clin Oncol; 1988 May; 6(5):839-53. PubMed ID: 3259261
[TBL] [Abstract][Full Text] [Related]
17. Development of new immunologic approaches to cancer therapy.
Rosenberg SA
Blood Purif; 1988; 6(2):69-76. PubMed ID: 3293619
[TBL] [Abstract][Full Text] [Related]
18. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
19. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
